OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

Please provide your email address to receive an email when new articles are posted on . Cystoscopies for recurrent UTIs yield little clinical benefit for patients both with and without high-risk ...

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder ...

The guidelines state that clinicians should offer blue light cystoscopy, if available, as an adjunct to traditional white light cystoscopy (WLC) to increase tumor detection and decrease recurrence.